Tvardi Therapeutics is trading 9.72% down at $1.13, versus the September 30 close of $1.25; no clear company-specific catalyst was identified for the pre-market move. - Shares closed lower on September 29 and September 30, following a sharp September 25 gain and losses earlier in the week. - The investor-relations page lists an August 26 investor-events notice as its latest announcement. Broader market indicators are mixed and do not clearly explain the stock-specific decline.